Blog

JERUSALEM, IL / ACCESS Newswire / August 21, 2025 / AppYea Inc. (OTCQB:APYP) today announced a strategic business pivot with the acquisition of Techlott Ltd.’s proprietary blockchain-based lottery and gaming platform. The transaction refocuses AppYea on the rapidly growing institutional lottery market, providing a complete, production-ready technology package engineered for enterprise deployments.

Why Techlott is a Game-Changer?

Techlott’s platform addresses the core weaknesses of legacy lottery systems-high costs, opacity, and slow scaling. Its Web3 architecture is built for today’s market:

• Engineered for Public Trust: The system puts governance and compliance at its core. It features on-chain draw logic, verifiable randomness, and an immutable audit trail-all essential for regulators and government ministries. This design helps build public trust by providing full transparency.

• Significantly Lower Operating Costs: Unlike legacy systems that rely on complex infrastructure and large back-office teams, Techlott’s design automates core workflows and reduces operational overhead. We project this can lead to up to significant lower operating costs for our partners.

• Security and Readiness: The platform’s smart contracts have passed an independent QuillAudits review with no high or medium-severity issues. The system has successfully processed over 212,000 test transactions under transparency review, validating its readiness for national-scale use.

• Built for Flexibility: The stack supports B2G, B2B, and B2C models, allowing for broad commercial deployment. It integrates with multiple blockchain networks and supports hybrid fiat-crypto payments.

Global Lottery Market: A Massive, Under-Digitized Opportunity

Independent market data consistently shows a very large and expanding market:

• Grand View Research: $353.29B (2024), forecast to reach $483.93B by 2030.

• Verified Market Research: $327.44B (2024), forecast to reach $402.42B by 2032.

With only ~16% of global lottery activity currently online, the market is poised for digital migration. Techlott’s platform is uniquely positioned to capture this significant opportunity.

Next Steps & Capital Markets

As part of the transaction, AppYea is aligning with Techlott’s team, with Techlott becoming a significant shareholder and gaining board representation. We will focus on:

1. Technology Integration & Commercialization: Rapidly integrating the platform and initiating go-to-market efforts focused on government and enterprise deployments.

2. Applying to uplist to a US Exchange: Advancing preparations for a potential uplisting application and related financing activities to support scaled operations.

Executive Commentary

Yakir Abadi, Chief Executive Officer, AppYea:

“This acquisition is the culmination of a clear strategy. We identified a gap in a multi-billion dollar market and acquired the technology to fill it. Regulators and ministries worldwide are seeking transparency and efficiency, and Techlott delivers exactly that. Our plan is simple and focused: integrate, sign anchor partners, and prepare for our next chapter on a major exchange.”

Mark Katzenelson, Founder, Techlott:

“After years of development and millions of dollars invested, our platform is ready for prime time. Teaming with AppYea gives us the public-market presence and governance needed to deploy our technology at institutional and national scale. This partnership is a catalyst for our growth.”

Eldar Edmond Grady, Chairman, AppYea:

“We are now a technology-driven company with a clear product, a solid execution plan, and a path to growth. Our focus is on disciplined delivery: bringing the technology to market, securing key contracts, and strengthening our capital structure to drive long-term value for our shareholders.”

Additional information on the transactions are provided in AppYea’s current report on Form 8-K filed with the Securities and Exchange Commission.

About Techlott Ltd.

Techlott Ltd. is a Cyprus‑incorporated technology company specializing in lottery and gaming platforms for regulated environments. Under the parties’ definitive agreements, AppYea is acquiring Techlott’s software (including source code), documentation, and related IP, positioned for institutional‑grade commercialization.

Safe Harbor Statement:

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of AppYea are subject to many factors including, but not limited to, the sufficiency or working capital to realize our business plans and new strategic direction, the going concern qualification in our financial statements, our ability to penetrate the new intended markets, our success in integrating the platform and initiating go-to-market efforts, our success in uplisting to a US exchange, the introduction of competitive products, the impact of any adverse litigation, commercialization and technological difficulties, and the other risks identified in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on April 15, 2025. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

Investor Relations Contact:
Golmidas Communications
Email: info@golmidas.com

SOURCE: APPYEA, Inc.

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences:

Morgan Stanley’s 23^rd Annual Global Healthcare Conference, on Monday, September 8^th at 10:00am ET

Bernstein Insights: Healthcare Leaders and Disruptors, on Thursday, September 25^th at 10:30am ET

A live webcast of each of these presentations will be available under “Events and Presentations” in the Investors section of the Moderna website.

investors.modernatx.com.

A replay of each webcast will be archived on Moderna’s website for at least 30 days following the presentation.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Media Contacts

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

Advanced Care Specialists is Bringing Not Just Medical Care, but True Advocacy

RACINE, WISCONSIN / ACCESS Newswire / August 21, 2025 / Advanced Care Specialists (ACS), Racine’s premier provider of multidisciplinary medical care, is proud to announce a renewed focus on helping injured workers with a streamlined, patient-first approach that’s changing the face of occupational injury treatment in Wisconsin.

The Problem: Delays, Denials, and Disjointed Care

Every year, countless Wisconsin workers suffer injuries on the job, ranging from repetitive strain and back pain to traumatic incidents and long-term occupational illnesses. Unfortunately, many face a frustrating road to recovery, especially federal workers trying to navigate the complex Department of Labor (DOL-OWCP) claims process. Between confusing paperwork, denied claims, and a lack of specialized medical support, injured workers are often left feeling overwhelmed and under-cared for.

That’s where Advanced Care Specialists steps in.

The Solution: Comprehensive, Coordinated Care Under One Roof

ACS provides a one-stop solution for injured workers, offering medical care, physical therapy, chiropractic services, joint injections, and advanced Class IV infrared laser therapy-all in one location. What truly sets them apart is their expertise in managing federal injury cases, guiding patients through CA-1 and CA-2 forms, coordinating with case managers, and even helping appeal denied claims. Their work conditioning programs are uniquely designed to get patients back to work stronger, safer, and fully prepared for the demands of their job.

As the only clinic in the state specializing in DOL-OWCP federal work injury claims, ACS offers a full-service solution for workers navigating the complex world of federal workers’ compensation. From initial injury reports (CA-1 and CA-2) to case management, appeals, and long-term treatment, ACS guides patients every step of the way. Helping patients recover faster, return to work safely, and regain quality of life.

“We believe injured workers deserve more than a Band-Aid fix. Our mission is to get them back to full strength, back to their lives, and back to work-safely and confidently,” said Dr. Nic Kampfer, Work Injury Specialist at ACS. “We’re not just treating injuries; we’re restoring function, dignity, and hope.”

Why ACS is Making Headlines:

• Unmatched Expertise: ACS is the only clinic in Wisconsin fully equipped to handle federal work injury cases through the Department of Labor’s Office of Workers’ Compensation Programs (OWCP).

• Comprehensive Care: Services include physical therapy, chiropractic care, massage therapy, joint injections, and Class IV infrared laser therapy, and more -all under one roof.

• Work Conditioning Programs: Tailored to each patient’s job and goals, ensuring a safe and sustainable return to work.

• Patient Advocacy: ACS empowers workers to know their rights-including the right to choose their doctor-and helps them cut through the red tape of injury claims.

Whether you’re a federal employee, postal worker, or anyone hurt on the job, ACS is your partner in recovery.

For more information, visit advancedcarespecialists.com/services/work-injury or call (262) 898-9000.

About Advanced Care Specialists
Advanced Care Specialists (ACS) is a multidisciplinary medical clinic proudly serving the Racine, Wisconsin community with a commitment to delivering high-quality, patient-centered care. ACS offers a wide range of services including primary care, physical therapy, chiropractic care, interventional pain management, advanced wound care, hyperbaric oxygen therapy, regenerative medicine, massage therapy, and specialized programs for work injuries and federal workers’ compensation (DOL-OWCP). With an integrated team of healthcare professionals and a focus on collaborative treatment, ACS is dedicated to helping patients achieve lasting relief, improved mobility, and better overall health. Whether recovering from injury, managing chronic conditions, or striving for wellness, ACS is a trusted partner in long-term care and healing. For more information, visit www.advancedcarespecialists.com or call (262) 898-9000.

Media Contact:
Hannah Kearney
Marketing & Communications
Advanced Care Specialists
Email: info@advancedcarespecialists.com
Phone: (262) 898-9000

SOURCE: Advanced Care Specialists

View the original press release on ACCESS Newswire

Esteemed expert in the regulation and development of biopharmaceuticals, with more than three decades of experience spanning government, industry, and academia

MIAMI, FL / ACCESS Newswire / August 21, 2025 / iTolerance, Inc. (“iTolerance” or the “Company”), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced the appointment of Emily Shacter, Ph.D. to the Company’s Scientific Advisory Board. Dr. Shacter has been supporting CMC development for iTolerance since February 2024.

“We are honored to welcome Dr. Shacter to our Scientific Advisory Board. With decades of experience as a leader in the regulation and development of biopharmaceuticals, we believe the insight Dr. Shacter will be instrumental as we continue to transition to a clinical-stage company and advance our therapies as a potential cure for Type 1 Diabetes. This appointment further strengthens our ability to navigate complex regulatory pathways, potentially accelerate clinical translation and unlock the full potential of our pipeline. Additionally, Dr. Shacter’s addition to our Scientific Advisory Board reflects our steadfast commitment to investing in the talent and guidance for iTolerance that we believe is needed to become a leader in the rapidly evolving regenerative medicine market,” commented Anthony Japour, Chief Executive Officer of iTolerance.

Dr. Shacter added, “Throughout my career at the FDA and in industry, I have seen firsthand both the challenges and opportunities involved in developing complex biological products. iTolerance’s platform technology, with its potential to enable tissue, organoid, and cell therapies without the need for life-long immunosuppression, provides an opportunity to address a profound unmet need in the field. I look forward to applying my experience to help guide the Company’s scientific and regulatory strategy as it moves toward clinical translation.”

Dr. Shacter is an esteemed expert in the regulation and development of biopharmaceuticals who served for nearly two decades at in the Division of Therapeutic Proteins of the Office of Biotechnology Products in the FDA’s Center for Drug Evaluation and Research (CDER). Her FDA career focused on oversight of biochemical characterization, manufacturing and control of complex protein therapeutics, including biosimilars and breakthrough biologics. As former Chief of the Laboratory of Biochemistry in the FDA’s CDER, she oversaw the review of numerous INDs and BLAs, played a role in shaping regulatory policy and advancing the science of biologics review, ran a laboratory research program, and oversaw the research of the principal investigators in her group. The research carried out in her laboratory provided the expertise required to understand and regulate complex biological products. Since 2012, she has served as an independent consultant, advising biotechnology companies on scientific and regulatory strategy for biologic drug development.

Additional career highlights include:

• Served as an FDA scientific advisor to the World Health Organization (WHO) for the development of international biosimilar guidelines;

• Engaged in FDA advisory and leadership roles, including the CDER Biosimilars Review Committee, Follow-on Biologics Working Group, and various CMC policy development efforts;

• Served as an editor and board member for major scientific journals including Free Radical Biology and Medicine and Journal of Biological Chemistry;

• Was an invited speaker and organizer at over 50 national and international conferences focused on biologics regulation, biosimilars, and analytical science;

• Authored or co-authored over 75 peer-reviewed publications in fields including protein oxidation, cell regulation, immunology, and cancer biology; and

• Received multiple FDA awards including the CDER Excellence in Mentoring Award and Center for Biologics Evaluation and Research Scientific Achievement Award for Excellence in Laboratory Science.

In addition to her decorated career in government and industry, Dr. Shacter’s research made significant contributions to understanding the molecular mechanisms of apoptosis, particularly in the context of cancer and inflammation. Her work focused on how reactive oxygen species produced during inflammation-such as hydrogen peroxide and taurine chloramine-affect the ability of chemotherapy drugs to induce apoptosis in cancer cells. She discovered that oxidative stress can inhibit both tumor cell death and the immune clearance of dying cells, and that antioxidants can restore chemotherapy efficacy. Dr. Shacter also identified the actin-regulating protein cofilin as a key intracellular redox sensor whose oxidation triggers mitochondria-dependent apoptosis. Additionally, she uncovered a novel role for the anticoagulant protein S in promoting macrophage phagocytosis of apoptotic cells. These findings provided critical insights into the interplay between inflammation, oxidative stress, and cell death, with implications for improving cancer therapies.

Dr. Shacter holds a Ph.D. in Biochemistry from Johns Hopkins University, completed in partnership with the National Institutes of Health, and a B.Sc. in Zoology from the University of Maryland.

About iTolerance, Inc.

iTolerance is a regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic cadaveric and stem cell-derived pancreatic islets to potentially cure Type 1 diabetes. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.

All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, anticipated levels of revenues, future national or regional economic and competitive conditions, and difficulties in developing the Company’s platform technology. Consequently, forward-looking statements should be regarded solely as the Company’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. The Company cannot guarantee future results, events, levels of activity, performance or achievements. The Company does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
iTolerance@jtcir.com

Media Contact
Susan Roberts
T:202.779.0929
sr@roberts-communications.com

SOURCE: iTolerance, Inc.

View the original press release on ACCESS Newswire

HARRISBURG, PENNSYLVANIA / ACCESS Newswire / August 21, 2025 / Crump Life Insurance Services, one of the nation’s largest insurance wholesalers, recently announced that Caroline “Carly” Brooks, JD, CLU^©, CFP^©, has joined the organization leading their Advanced Sales team.

“Advanced sales is one of the cornerstones of our offering to the financial professionals we serve, and we are thrilled to have Carly join our team to lead this critical function for us,” said Mike Martini, President and CEO of Crump Life Insurance Services.

Brooks joins Crump as Senior Vice President and will lead Crump’s team of advanced sales specialists who focus on complex concepts and strategies within estate, wealth, and retirement planning. Bringing well over a decade of industry experience, Brooks most recently served as AVP and Counsel, Head of Advanced Markets for John Hancock Financial. Prior to John Hancock, she served in roles in wealth strategies and financial planning, progressing through positions of increasing responsibility. She is a frequent speaker at industry conferences and events and holds several positions on industry and legal boards and committees.

“The excitement from both our Crump teammates and our external clients about Carly joining Crump is palpable,” said Rob Stern, Chief Administration Officer for Crump who has oversight for advanced sales. “Carly has an impressive track record and has made a name for herself as a leading voice in the advanced markets space. We know Carly will be a great complement to the strong skills and knowledge within our advanced sales team. Carly’s passion and purpose coupled with Crump’s resources and carrier and client relationships position us for continued growth and success.”

About Crump

Crump Life Insurance Services is a leading third-party distributor and service provider of insurance and retirement products. Crump supports the distribution of traditional and variable life, annuity, long term care, linked benefits, disability, and health products with the industry’s premier sales and back-office support and technology services, marketing under the following brands: Truist Life Insurance Services, Tellus, and Hanleigh.

Contact Information

Jane DeMuth
Vice President, Marketing
jane.demuth@crump.com
717-736-7967

SOURCE: Crump Life Insurance

View the original press release on ACCESS Newswire

Parent company of Condo Control and HOA Sites introduces a modern platform that cuts costs, automates busy work, and improves resident experience.

INDIANAPOLIS, INDIANA / ACCESS Newswire / August 21, 2025 / Property Control, the parent company of Condo Control and HOA Sites, today announced the launch of HOA Central, a mobile-first platform that unifies community operations, payments, compliance, and communications in one secure hub. The product is built to help boards and managers manage with confidence and residents live with ease.

“Running an HOA should not require multiple systems and a spreadsheet,” said Brian Bosscher, CEO of Property Control. “With HOA Central, teams move requests, payments, and records into one place so they spend less time chasing tasks and more time improving their communities.”

Built by the team behind Condo Control, trusted by more than 7,000 communities, HOA Central pairs consumer-grade mobile portals with AI-powered automation and deep integrations to tools HOAs already use, including QuickBooks, Yardi, and Stripe. Early customers can target up to 40% lower operating costs, 50% less manual work, and about 15 hours saved per week. Pricing is a transparent per-door rate with no storage or support add-ons.

Key capabilities

• Expert onboarding and support: white-glove setup, a named customer success manager, unlimited refresher training, and an on-demand video library with a 95% CSAT resident help line.

• Unified operations and compliance: maintenance, violations, documents, KPIs, meetings, elections, and payments in one place, with minutes and election records for audits.

• Resident experience: a mobile-first portal with a digital bulletin, e-voting, surveys, and QR guest passes that drive 85% plus adoption.

• No double-entry accounting and payments: syncs dues, late fees, and vendor invoices directly into QuickBooks, VMS, Yardi, or other accounting platforms.

• AI-powered automation: instant answers to FAQs and a 24/7 chatbot.

• Best-practice library: more than 50 state-specific templates covering announcements, ARC forms, violations, and election notices.

What makes it different

HOA Central is designed for high adoption and reliability. Communities benefit from a resident-centric user experience that is 96% rated “easy to use,” average resident uptake of 85%, and 99.9% uptime with zero-downtime maintenance. Managers, boards, and residents all receive phone, email, and video support, and the product ships weekly improvements and new features.

Built for self-managed boards and management firms

Whether consolidating point solutions or launching a first digital program, both self-managed HOAs and community management companies can standardize workflows, records, and reporting across communities, and scale at their own pace.

About Property Control

Property Control is the parent company of Condo Control and HOA Sites. The company builds modern software that digitizes, streamlines, and automates community operations for boards, managers, and residents.

About HOA Central

HOA Central delivers a future-proof, all-in-one operating system that slashes workload, controls costs, and elevates the livability of every HOA it touches. The mission is to give HOAs the digital tools, guidance, and insight they need to reduce costs, stay compliant, and foster thriving neighborhoods.

Contact Information

Phillip Livingston
Director of marketing
inquiries@hoacentral.com
12138781992

SOURCE: HOA Central

View the original press release on ACCESS Newswire